Peptide-based PROTACs: Current Challenges and Future Perspectives

• Published in: Current medicinal chemistry
• Main Authors: Wang, Huidan, Chen, Miao, Zhang, Xiaoyuan, Xie, Songbo, Qin, Jie, Li, Jingrui
• Format: Journal Article
• Language: English
• Published: United Arab Emirates 01.01.2024
• Subjects: Delivery; Peptide-based PROTAC; Undruggable protein; Targeted protein degradation
• ISSN: 1875-533X
• DOI: 10.2174/0929867330666230130121822

Proteolysis-targeting chimeras (PROTACs) are an attractive means to target previously undruggable or drug-resistant mutant proteins. While small molecule-based PROTACs are stable and can cross cell membranes, there is limited availability of suitable small molecule warheads capable of recruiting proteins to an E3 ubiquitin ligase for degradation. With advances in structural biology and in silico protein structure prediction, it is now becoming easier to define highly selective peptides suitable for PROTAC design. As a result, peptide-based PROTACs are becoming a feasible proposition for targeting previously "undruggable" proteins not amenable to small molecule inhibition. In this review, we summarize recent progress in the design and application of peptide-based PROTACs as well as several practical approaches for obtaining candidate peptides for PROTACs. We also discuss the major hurdles preventing the translation of peptide-based PROTACs from bench to bedside, such as their delivery and bioavailability, with the aim of stimulating discussion about how best to accelerate the clinical development of peptide-based PROTACs in the near future.